Late Results After Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism Using the Amplatzer PFO Occluder Without Intraprocedural Echocardiography Effect of Device Size by Wahl, Andreas et al.
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f Patent Foramen Ovale for Secondary
revention of Paradoxical Embolism Using
he Amplatzer PFO Occluder Without
ntraprocedural Echocardiography
ffect of Device Size
ndreas Wahl, MD,* Tony Tai, MD,* Fabien Praz, MD,* Markus Schwerzmann, MD,*
hristian Seiler, MD,* Krassen Nedeltchev, MD,† Stephan Windecker, MD,*
einrich P. Mattle, MD,† Bernhard Meier, MD*
ern, Switzerland
bjectives We sought to assess the safety and clinical efﬁcacy of patent foramen ovale (PFO) clo-
ure under ﬂuoroscopic guidance only, without intraprocedural echocardiography.
ackground Percutaneous PFO closure has been shown to be safe and feasible using several de-
ices. It is generally performed using simultaneously ﬂuoroscopic and transesophageal or intracar-
iac echocardiographic guidance. Transesophageal echocardiography requires sedation or general
nesthesia and intubation to avoid aspiration. Intracardiac echocardiography is costly and has inher-
nt risks. Both lengthen the procedure. The Amplatzer PFO Occluder (AGA Medical Corporation,
olden Valley, Minnesota) can be safely implanted without echocardiographic guidance.
ethods A total of 620 patients (51  12 years; 66% male) underwent PFO closure using the Am-
latzer PFO Occluder for secondary prevention of presumed paradoxical embolism. Based on size
nd mobility of the PFO and the interatrial septum, an 18-mm device was used in 50 patients, a
5-mm device in 492, and a 35-mm device in 78.
esults All procedures were successful, with 5 procedural complications (0.8%): 4 arteriovenous
stulae requiring elective surgical correction, and 1 transient ischemic attack. Contrast transesopha-
eal echocardiography at 6 months showed complete closure in 91% of patients, whereas a mini-
al, moderate, or large residual shunt persisted in 6%, 2%, and 1%, respectively. During a mean
ollow-up period of 3.0  1.9 years (median: 2.6 years; total patient-years: 1,871), 5 ischemic strokes,
transient ischemic attacks, and no peripheral emboli were reported. Freedom from recurrent isch-
mic stroke, transient ischemic attack, or peripheral embolism was 99% at 1 year, 99% at 2 years,
nd 97% at 5 years.
onclusions The Amplatzer PFO Occluder affords excellent safety and long-term clinical efﬁcacy of
ercutaneous PFO closure without intraprocedural echocardiography. (J Am Coll Cardiol Intv 2009;
:116–23) © 2009 by the American College of Cardiology Foundation
rom the Departments of *Cardiology and †Neurology, University Hospital, Bern, Switzerland. Prof. Meier receives a research
rant from and serves on the Speakers’ Bureau of AGA Medical, Golden Valley, Minnesota. Drs. Tai and Praz contributed equally
o this paper.anuscript received September 16, 2008; accepted September 29, 2008.
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117he association of patent foramen ovale (PFO) with cryp-
ogenic stroke has been repeatedly confirmed (1,2) after
eing independently reported by Lechat et al. (3) and
ebster et al. (4) in 1988. A systematic review of case-
ontrol studies (1) established a strong association between
FO alone (odds ratio [OR]: 5.0; 95% confidence interval
CI]: 2.4 to 10.4) and especially of PFO associated with
trial septal aneurysm (ASA) (OR: 23.3; 95% CI: 5.2 to
03.2) in young adults (55 years) with cryptogenic
See page 124
troke compared with nonstroke controls. More recently,
his observation was extended to adults 55 years, with a
ignificantly higher prevalence of PFO alone (28.3% vs.
1.9%; OR: 2.9; 95% CI: 1.7 to 5.0; p  0.001) as well as
f PFO associated with ASA (15.2% vs. 4.4%; OR: 3.9;
5% CI: 1.8 to 8.5; p  0.001) among patients with
ryptogenic stroke compared with those with a known
troke cause (5). Percutaneous PFO closure has been shown
o be safe and feasible using a variety of devices (6–11), and
ts clinical efficacy for secondary prevention of paradoxical
mbolism appeared favorable when compared with medical
reatment (12–14). The reported success rates varied be-
ween 90% and 100%, with complication rates between 0%
nd 10%. Complete PFO closure was reported in 51% to
00% of patients, and the yearly recurrence rates of ischemic
trokes and transient ischemic attacks (TIA) varied between
% and 3.4%. Important differences were observed between
he devices used (11,15,16). Initial device-related complica-
ions inflicted by large delivery systems, device dislodgment
nd embolization, structural failure, thrombus formation
17), and inability to reposition or remove the device were
educed by improvements in device design. Anatomic and
Figure 1. Amplatzer PFO OccluderAmplatzer PFO Occluder (left) placed in a cadaver heart (right), seen from the righthysiologic differences between PFOs and atrial septal
efects led to the development of devices specifically de-
igned for percutaneous PFO closure. The Amplatzer PFO
ccluder (APFO) (AGA Medical Corporation, Golden
alley, Minnesota) is a self-expanding double-disk device
anufactured from 0.005-inch nitinol wire with a polyester
abric patch sewn into both disks (Fig. 1). It is fully
ecoverable and repositionable as long as it is attached to its
elivery cable (18). In contrast to the Amplatzer Septal
ccluder, the left atrial disk is smaller than the right (except
or the so-called cribriform models), and a thin and flexible
aist connects the 2 retention disks. Percutaneous PFO
losure is generally performed using simultaneous fluoro-
copic and transesophageal echocardiographic (TEE)
9,10,16) or intracardiac echocardiographic (ICE) (19, 20)
uidance. Whereas TEE requires sedation or general anes-
hesia and intubation to avoid aspiration, ICE is costly and
as inherent risks. Moreover, both imaging modalities
onsiderably lengthen the proce-
ure.
ethods
atients. Between November
998 and December 2006, 620
atients underwent percutane-
us PFO closure for secondary
revention of presumed para-
oxical embolism using the
PFO. An embolic event was
onsidered to be due to paradox-
cal embolism when the follow-
ng criteria were fulfilled: the
resence of PFO with or with-
Abbreviations
and Acronyms
APFO  Amplatzer PFO
Occluder
ASA  atrial septal
aneurysm
CI  confidence interval
ICE  intracardiac
echocardiography
OR  odds ratio
PFO  patent foramen ovale
TEE  transesophageal
echocardiography
TIA  transient ischemic
attackatrium. Courtesy of AGA Medical. PFO  patent foramen ovale.
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118ut ASA with spontaneous or inducible interatrial right-to-
eft shunt during contrast TEE, clinically and/or radiolog-
cally confirmed ischemic stroke, TIA, or peripheral
mbolism, and exclusion of any other obvious cardiac,
ortic, or cerebrovascular cause. The procedure was ap-
roved by the local ethics committee, and patients gave
ritten informed consent.
chocardiography. The diagnosis of PFO and ASA was
ased on contrast TEE, with aerated colloid solution
njected into an antecubital vein at the end of a vigorous and
ustained Valsalva maneuver. We defined PFO as a flaplike
pening in the atrial septum secundum, with the septum
rimum serving as a 1-way valve allowing for permanent or
ransient right-to-left shunt. We diagnosed ASA as an
bnormally redundant interatrial septum with an excursion
f 10 mm into the right or left atrium and a diameter at
he base of the aneurysm of at least 15 mm (21). Sponta-
eous or provoked right-to-left shunt was semiquantita-
ively graded according to the amount of bubbles detected in
he left atrium after crossing the interatrial septum on a still
rame: grade 0 none, grade 1 minimal (1 to 5 bubbles),
rade 2  moderate (6 to 20 bubbles), and grade 3  severe
20 bubbles) (4). To unequivocally demonstrate the pres-
nce of a PFO, care was taken to document the actual
assage of contrast bubbles through the rent, but this was
ot possible in all cases.
PFO. The APFO was commercially available in 3 sizes,
ith the dominant right atrial disk measuring 18, 25, or 35
m, and the left atrial disk measuring 18, 18, and 25 mm,
espectively. It can be constrained within an 8-F (9-F for
he largest model) delivery system and reassumes its double-
isk shape upon release.
ercutaneous PFO closure. The interventions were per-
ormed under local anesthesia and fluoroscopic guidance
nly (7). Intraprocedural guidance by TEE (9,10,16) or
CE (19,20) was not used in any case. However, all patients
ad undergone TEE prior to the intervention for initial
iagnosis of PFO. After venous access was gained via the
ight femoral vein, the PFO was crossed under fluoroscopic
uidance in the anteroposterior view either by a standard
ength normal 0.035-inch guidewire alone or with the help
f a catheter, typically a 6-F multipurpose catheter. Initially,
J-tip was used to ensure passage through the largest hole
n case there were several. In some cases (small PFO), the
ip had to be straightened for passage of the defect. Balloon
izing was not used. Indeed, the maximal opening of the
aplike PFO is not instrumental for the success of closure.
oreover, there is a finite risk of the measuring balloon
earing the thin septum primum (22). A 25-mm device was
elected for all cases, save those with particularly low
obility (18 mm) or extremely long tunnel (35 mm). In 5%
f cases, the initial device had to be exchanged for a larger
evice during the procedure because of suboptimal anchor-ng (negative Pacman sign) (Fig. 2) (23). The device was mrepared before introducing the sheath to keep the indwell-
ng time of the sheath short. To avoid air aspiration, the
bturator of the sheath was pulled back while the guidewire
emained in the left atrium or a pulmonary vein. This avoids
edging of the end hole against the wall and allows the
lood to follow the receding obturator, filling the void
ather than air being sucked in from the outside. The loader
as connected to the sheath with the device peeking out a
ew millimeters, lateral to the patient’s thigh, well below the
eart level. The APFO was then pushed with the delivery
able to the tip of the sheath positioned in the left atrium.
he left atrial disk was deployed and gently pulled back
gainst the atrial septum under fluoroscopic guidance in a
eft anterior oblique projection. To deploy the right atrial
isk, tension was maintained on the delivery cable while
urther withdrawing the delivery sheath. After aspiration of
he air from the sheath, a right atrial contrast angiography
y a hand injection through a sidearm of the delivery sheath
elineated the atrial septum. The so-called Pacman sign
23) (Fig. 2) refers to the aspect of the device on fluoroscopy
hat should be achieved before release. Seen in perfect
rofile, the cranial halves of the left and right atrial disks
hould appear like open jaws biting into the thick septum
ecundum, reminding one of the arcade game figure Pac-
an about to gobble up a dot. Upon verification of correct
osition, the APFO was released by unscrewing the delivery
able in counterclockwise fashion. The transseptal sheath
as then used for a final contrast medium injection. The
ontrast can be followed through to the levo-phase to also
elineate the left atrial contour and disk placement. Finally,
he sheath was removed and hemostasis achieved by light
Figure 2. Pacman Sign for Angiographic Assessment of Correct
Device Position
The Pacman sign (23) illustrated with the proper projection of the device
during a hand injection of contrast medium into the right atrium (RA). The
septum secundum (*) represents the dot the device (represented by Pac-
man) is biting into.anual compression, often done by the patient himself.
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119atients were released to full physical activity a few hours
fter the procedure. A transthoracic contrast echocardiog-
aphy was performed within 24 h of percutaneous PFO
losure to document correct and stable device position.
cetylsalicylic acid 100 mg once daily for 6 months and
lopidogrel 75 mg once daily for 1 to 6 months were
rescribed for antithrombotic protection.
ollow-up evaluation. The outcome after the intervention
as prospectively assessed for up to 8 years. A contrast TEE
as repeated 6 months after percutaneous PFO closure. In
ase of a significant residual shunt, a repeat TEE at 1 year
as recommended. If the shunt persisted at that time,
mplantation of a second device was recommended. There-
fter, patients underwent structured telephone interviews,
ddressing recurrent embolic events, device-related prob-
ems, and health status at regular intervals. Follow-up
nformation was available for all patients, but 19 patients
3%) were eventually lost to follow-up. Death and recurrent
schemic stroke, TIA, or peripheral embolism were consid-
red end points. Patients with suspected recurrent cerebro-
ascular events were re-examined by a neurologist, and a
ew imaging study of the brain (computed tomography or
agnetic resonance imaging) was performed.
tatistical analysis. Continuous variables are expressed as
ean  1 standard deviation, and were compared by a
-sided, unpaired t test. Categorical variables are reported as
ounts and percentages and were compared by chi-square
nalysis. Estimates for freedom from the composite of
ecurrent TIA, stroke, and peripheral embolism were ob-
ained using the Kaplan-Meier method. The log-rank test
as used for univariate analysis of independent predictors of
ecurrence. Estimates of the hazard ratio (HR) and 95%
onfidence intervals for each independent variable were
btained by proportional hazard regression analysis. Statis-
ical significance was assumed with a p value0.05. All data
ere analyzed by SPSS software version 15.0.1 (SPSS Inc.,
hicago, Illinois).
esults
n-hospital outcome. Demographic data are summarized in
able 1. All implantation procedures were successful (Table
). There were 5 procedural complications (0.8%): 4 arte-
iovenous fistulae at the puncture site requiring elective
urgical closure (2 in patients with concomitant coronary
ngiography) and 1 TIA with visual symptoms (immedi-
tely after PFO closure). There were no in-hospital deaths,
nd none of the procedural complications resulted in long-
erm sequelae. Total procedure time, including incidental
oronary angiography (24) in 439 patients (71%), and ad
oc percutaneous coronary intervention in 44 (7%), was 40
21 min (median: 36 min). Total fluoroscopy time was 7.3
6.6 min (median: 5.5 min). In the 181 patients under-oing PFO closure only, the total procedure time amounted io only 25  12 min (median: 22 min), and the fluoroscopy
ime was 3.8  2.5 min (median: 3.1 min). Patients with
mall occluders (18 and 25 mm; n  542 patients) had
imilar complication rates (0.7% vs. 1.3%; p  0.62)
ompared with patients with large occluders (35 mm; n 
8). Patients with an associated ASA (n  207; 33%) had
imilar complication rates (1.4% vs. 0.5%; p  0.21)
ompared with patients with an isolated PFO (n  413;
6%). Patients 55 years (n  264; 43%) and 55 years
n 356; 57%) also had similar complication rates (1.1% vs.
.6%; p  0.43). Transthoracic contrast echocardiography
fter the Valsalva maneuver within 24 h of percutaneous
FO closure (performed in all patients) detected a residual
hunt in 11% of patients.
ate echocardiographic outcome. Complete PFO closure as
ssessed by contrast TEE (performed in 94% of patients)
fter the Valsalva maneuver at 6 months was achieved in
1% of patients, whereas a minimal, moderate, or large
esidual shunt persisted in 6%, 2%, or 1% of patients,
espectively (Fig. 3). Patients with 18- and 25-mm devices
n  542) had considerably fewer residual shunts compared
ith patients with 35-mm devices (n  78), that is, 7%
ersus 27%, respectively (p  0.001) (Fig. 4). Older (55
ears; n  264; 43%) and younger (55 years; n  356)
atients had similar residual shunt rates (9% vs. 9%; p 
.92). Patients with PFO and an associated ASA (n  207;
3%) had higher residual shunt rates than patients with an
Table 1. Baseline Clinical Characteristics
Patients 620
Age, yrs 51 12 (median: 53)
Male 377 (66%)
Height, cm 173 9
Weight, kg 76 15
Atrial septal anatomy
Left atrial size, mm 37 6
Associated atrial septal aneurysm 207 (33%)
Cardiovascular risk factors
Arterial hypertension 198 (32%)
Diabetes mellitus 26 (4%)
Smoking history 188 (30%)
Total cholesterol, mmol/l 5.2 1.1
Embolic index event
Ischemic stroke 358 (58%)
Transient ischemic attack 228 (37%)
Peripheral embolism 34 (5%)
Number of clinically apparent prior embolic events
1 429 (69%)
2 101 (16%)
3 25 (4%)
4 or more 63 (10%)
Values are n (%) or mean SD.solated PFO (n  413; 67%), that is, 13% versus 7%,
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120espectively (p  0.05). At 6-month follow-up, contrast
EE examination showed a thrombus on the device in 3
symptomatic patients (0.5%). One patient (25-mm
PFO) had a tiny thrombus on the left atrial disk, which
emained unchanged after 4 months of oral anticoagulation.
ne patient (35-mm APFO) had a small thrombus on the
eft atrial disk, which resolved after 3 months of oral
nticoagulation. Another patient had a 20  7 mm throm-
us adherent to the right atrial disk (35-mm APFO) that
esolved after 6 months of oral anticoagulation. Ten months
fter cessation of oral anticoagulants, TEE showed a recur-
ent right atrial thrombus, which resolved once again after
ral anticoagulant therapy during 6 months, without further
ecurrences. The last echocardiography at the 7-year
ollow-up was normal.
A total of 8 patients (1.3%), 4 of them with an ASA, with
18-mm and 7 25-mm devices in place, underwent im-
lantation of a second device (1 APFO 18-mm and 7
PFO 25-mm) due to a significant residual shunt. In all of
hese patients, TEE showed the initial closure device in the
orrect position, but a residual shunt in the region of the
ormer PFO. No periprocedural complications occurred
uring the second intervention. After implantation of the
Table 2. Implanted Amplatzer PFO Occluder Devices
Device
Size Patients
Atrial Septal
Aneurysm
Baseline
PFO-Mediated Shunt
Proce
Compli
18-mm 50 20% 4% grade 1
16% grade 2
80% grade 3
0
25-mm 492 31% 2% grade 1
18% grade 2
80% grade 3
0.8
35-mm 78 58% 3% grade 1
14% grade 2
83% grade 3
1.3
Total 620 33% 0.8
PFO patient foramen ovale; TEE transesophageal echocardiography.
Figure 3. Interatrial Shunt at Baseline and 6 Months After Device Implanta
A patent foramen ovale (PFO)-mediated interatrial shunt at baseline and 6 mo
transesophageal echocardiography.econd device, complete closure was finally achieved in 6 of
patients (75%), with persistence of a mild and a moderate
esidual shunt in 1 patient each.
In a patient with a PFO grade III associated with a
arge ASA, TEE 2 years after implantation of an APFO
5-mm device (performed due to persistence of a residual
hunt after 6 months) disclosed a new tiny atrial septal
efect at the lower rim of the device, probably corre-
ponding to an erosion of the interatrial septum due to
he wear and tear of the ASA undulating incessantly
etween the right and left disk of the device. In another
atient, routine TEE 6 months after implantation of an
PFO 25-mm device showed a completely occluded
FO, but a new small atrial septal defect was seen at the
ower rim of the device. In both cases, these iatrogenic
mall atrial septal defects were successfully closed using a
5-mm APFO (25). There were no further device-related
omplications, in particular no dislocations or erosions of
he free atrial walls.
ate outcome. During 3  1.9 years of follow-up (median:
.6 years; total patient-years: 1,871), 9 deaths (3 accidents,
cancer, 2 ventricular fibrillation, 1 infection, 1 coma due to
rolonged hypoglycemia), none of them related to recurrent
s
Residual Shunt
(Contrast TEE at 6 Months)
Recurrent
Embolism
Cumulative Follow-Up
(Patient-Yrs)
7% 1 157
7% 11 1,395
27% 1 319
9% 13 1,871
fter percutaneous closure of PFO, as assessed by contrastdural
cation
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121mbolic events; 5 ischemic strokes, 8 TIAs and no periph-
ral emboli were reported. Symptomatic paroxysmal atrial
brillation was documented in 10 cases only (1.6%; mean
ge: 61 years; range: 51 to 74 years) but was not specifically
ooked for in all patients. Freedom from the composite end
oint of recurrent ischemic stroke, TIA, or peripheral
mbolism was 99% at 1 year, 99% at 2 years, and 97% at 5
ears, respectively (Fig. 5). The presence of multiple clinical
mbolic events prior to PFO closure was a risk factor for
ecurrence (HR: 4.9; 95% CI: 1.5 to 15.9; p  0.008). On
he other hand, male gender was associated with less
ecurrent events (HR: 0.2; 95% CI: 0.1 to 0.8; p  0.03).
ontrary to previously reported findings by our group in a
maller cohort with different devices (7,8,11), a residual
ight-to-left shunt after transcatheter treatment of PFO was
ot a predictor of recurrent events (HR: 0.9; 95% CI: 0.1 to
.7; p  0.89). Older age (55 years), the presence of an
SA associated with the PFO, arterial hypertension, dia-
etes mellitus, smoking status, family history, hypercholes-
erolemia, device size, and procedural complications did not
Figure 4. Interatrial Shunt 6 Months After Device Implantation for
Different Device Sizes
A patent foramen ovale (PFO)-mediated interatrial shunt at 6 months after
percutaneous closure of patent foramen ovale for different sizes of
Amplatzer PFO Occluders, as assessed by contrast transesophageal
echocardiography.dversely affect the outcome either.iscussion
his study is the largest series of patients with presumed
aradoxical embolism treated at a single center and with one
f the longest follow-ups reported to date to investigate the
afety, feasibility, and long-term clinical efficacy of percuta-
eous PFO closure using the APFO. Moreover, the proce-
ure was performed without intraprocedural echocardiogra-
hy in all patients. To our knowledge, there is only 1 large
tudy reporting mid-term results after percutaneous PFO
losure using mostly APFO (20). In the study of Onorato et
l. (20), 248 of 256 patients received an APFO, which was
uccessfully implanted in all cases. Onorato et al. (20) used
CE in 69% of cases, and TEE in 31%. Procedure and
uoroscopy times were markedly longer than in our study, at
7  21 min and 9.5  5 min, respectively.
Our study confirms the safety and feasibility of percuta-
eous PFO closure with the APFO using the simple
echnique described in the Methods section in a large series.
he complication rate was 0.8%, and none of the compli-
ations had a connection to the omission of ultrasound
uidance. In contrast, the use of ICE would have com-
ounded the risk for puncture site problems accounting for
ll but 1 complication. Complete PFO closure could be
chieved in 91% of patients, and even 93% in patients with
maller devices (18- and 25-mm). During long-term follow-
p, the risk of recurrent events after transcatheter treatment
f PFO with or without associated ASA was 1% per year.
f note, recurrent embolic events occurred up to 5.3 years
fter PFO closure, which is considerably longer than the 8
onths reported by Braun et al. (16). The excellent clinical
Figure 5. Freedom From Recurrent TIA, Ischemic Stroke, and
Peripheral Embolism
Freedom from the composite end point of recurrent transient ischemic
attack (TIA), ischemic stroke, or peripheral embolism after percutaneous
closure of patent foramen ovale.
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122fficacy compares favorably with medical treatment (26).
ong-term device-related events (3 thrombi and 2 erosions
f the interatrial septum) were rare, and none had clinical
equelae. These are important safety findings for an inter-
entional treatment of a condition that has a low annual
vent rate in natural history.
In patients with both PFO and ASA, who constitute a
igh-risk population with a 3- to 5-fold increased risk for
ecurrent embolic events than for patients with PFO alone
1), secondary prevention with acetylsalicylic acid alone has
een found to be insufficient (27). In this series, an ASA
ssociated with PFO had no influence on device success or
n the risk of periprocedural complications or recurrent
vents. However, it was associated with an increased resid-
al shunt rate. Moreover, this series confirmed that percu-
aneous PFO closure is equally safe, feasible, and efficacious
n selected older (55 years) (28) and younger patients.
ndeed, the association between PFO alone and PFO with
SA with cryptogenic stroke has been recently extended to
dults 55 years (5), and the elderly who have the highest
isk (29,30) of paradoxical embolism should not be denied a
imple preventive treatment. The uncontested association of
FO and stroke renders the consideration of the PFO as a
troke cause only in cryptogenic strokes illogical. In older
eople, the diagnosis of cryptogenic stroke is rare, due to a
igh prevalence of stroke-associated disorders. Notwith-
tanding, a PFO per se might be more dangerous in them
han in younger people due to the increasingly high preva-
ence of venous thrombosis associated with age (30).
Transcatheter treatment of patients with cryptogenic
troke and PFO has been shown to be safe and feasible
sing a variety of occlusion devices, mostly with
9,10,16,28) but also without intraprocedural echocardio-
raphic guidance (7,8,31). Routine TEE guidance provides
ittle additional information to what can be gleaned from a
and injection of contrast medium (23) in a profile-adjusted
iew (Fig. 2). Because TEE is poorly tolerated by supine
atients, it comes at the cost of sedation or general anes-
hesia, including intubation to virtually exclude the risk of
ronchial aspiration. This considerably lengthens the pro-
edure. Although ICE (19,20) is a costly alternative that is
ore comfortable for the patient, it increases the invasive
isk (additional vascular access, second rigid, and unguided
ntravenous catheter, with potential complications including
evelopment of arteriovenous fistulae at the puncture site,
ir embolism through the introducer, cardiac perforation,
nd bacterial entry). In this large series of PFO closure
ithout intraprocedural TEE or ICE guidance, the device
uccess was 100%, and the 5 periprocedural complications
0.8%) were unrelated to the presence or absence of echo-
ardiography. Although this series did not include a control
roup with echocardiographic guidance, these rates compare
avorably with the published experience. Indeed, in studies
sing echocardiographic guidance, the complication rateseported varied between 0% and 9% (6,9,10,16,20,28). With
espect to closure rates, this study showed that larger
evices, selected for larger shunts in the presence of an
SA, were associated with considerably higher residual
hunt rates. However, this nonrandomized comparison was
iased in favor of smaller devices (e.g., only 30% of patients
eceiving an 18- or 25-mm device had an associated ASA
s. 58% for 35-mm devices; p  0.001). Although larger
evices are easier to implant and preferred by most operators
n case of larger PFOs or associated ASAs, there is more
oncern about the risk of impairment or erosion of adjacent
tructures. Smaller devices more snugly fit into the fossa
valis. However, they are intrinsically more likely to embo-
ize or to only partially cover a slitlike PFO or a cribriform
eptum primum.
tudy limitations. Because both PFO and cryptogenic
troke are prevalent conditions, they may coexist without
ausal relation in certain patients. Percutaneous PFO clo-
ure in patients with falsely PFO-related strokes will not
nfluence recurrent embolic events, a circumstance likely to
ontribute to the small recurrence rate despite successful
FO closure in our and other series. Nonetheless, these
atients will be protected against true paradoxical embolism.
t has to be emphasized that the true therapeutic efficacy of
ercutaneous PFO closure as an adjunct or alternative to
edical treatment can only be ascertained by randomized
tudies. While we wait for those studies, it is time to shift
he term “cryptogenic” in stroke patients to beyond the
xclusion of a PFO. A PFO is a reason for stroke, not more
ut not less.
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